Core Viewpoint - The company has successfully completed its second phase of A-share repurchase, acquiring a total of 1,832,421 shares, which represents 0.79% of its total share capital, with a total expenditure of approximately 103.91 million yuan [1][3][4]. Summary by Sections Repurchase Plan and Approval - The repurchase plan was first disclosed on August 17, 2024, with a total expected repurchase amount between 100 million yuan and 200 million yuan, and a maximum repurchase price of 89.71 yuan per share [1]. - The board approved the repurchase on August 16, 2024, and the implementation period is from August 16, 2024, to August 15, 2025 [1]. Adjustments to Repurchase Price - Following the implementation of the 2024 semi-annual equity distribution, the maximum repurchase price was adjusted from 89.71 yuan to 89.31 yuan per share [2]. - After the 2024 annual equity distribution, the maximum repurchase price was further adjusted to 88.72 yuan per share [2]. Implementation Status - The company initiated the repurchase on November 26, 2024, and completed the repurchase by August 14, 2025, acquiring a total of 1,832,421 shares at an average price of 56.70 yuan per share [3][4]. - The total funds used for the repurchase amounted to approximately 103.91 million yuan, excluding taxes and transaction fees [3]. Share Distribution Changes - Prior to the repurchase, the total share count was 235,489,895 shares, which decreased to 232,581,095 shares post-repurchase [4][5]. - The repurchased shares will be used for employee stock ownership plans or equity incentives and will not enjoy voting rights or profit distribution during the holding period [6]. Future Plans for Repurchased Shares - The repurchased shares are intended to be transferred within three years; if not transferred, they will be canceled and the registered capital will be reduced accordingly [6].

Group 1 - The company, Haohai Biological Technology (06826), announced the completion of its second phase of A-share buyback as of August 14, 2025 [1] - A total of 1.8324 million A-shares were repurchased, accounting for 0.79% of the company's total share capital [1] - The highest transaction price during the buyback was 63.58 CNY per share, while the lowest was 49.25 CNY per share, with an average buyback price of 56.70 CNY per share [1] - The total funds paid for the buyback amounted to 103.9 million CNY, excluding stamp duty and transaction commissions [1]

智通财经APP讯，昊海生物科技(06826)发布公告，关于第二期A股股份回购实施结果，截至2025年8月 14日，公司已完成本期回购。公司通过上海证券交易所系统以集中竞价交易方式已累计回购A股股份 183.24万股，占公司总股本比例为0.79%，回购成交的最高价为63.58元/股，最低价为49.25元/股，回购 均价为56.70元/股，支付的资金总额为人民币1.039亿元(不含印花税、交易佣金等费用)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期A股股份回購實施結果公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月15日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 一、 回购审批情况和回购方案内容 上海昊海生物科技股份有限公司 ...

Group 1 - The core business of Haohai Biological Technology is primarily in the pharmaceutical manufacturing sector, accounting for 99.83% of its revenue, while other businesses contribute only 0.17% [1] Group 2 - As of August 15, 2025, Haohai Biological Technology has completed its share repurchase program, acquiring approximately 1.83 million A-shares, which represents 0.79% of the total share capital of about 233 million shares [3] - The highest price for the repurchased shares was 63.58 CNY per share, the lowest was 49.25 CNY per share, and the average repurchase price was 56.7 CNY per share, with a total expenditure of approximately 104 million CNY [3]

证券代码：688366 证券简称：昊海生科 公告编号：2025-037 上海昊海生物科技股份有限公司 关于第二期 A 股股份回购实施结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/17 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 8 8 | 16 | 日~2025 | 年 | 月 | 日 15 | | 预计回购金额 | 10,000.00万元~20,000.00万元 | | | | | | | 回购价格上限 | 88.72元/股（调整前为 89.71 | | | | | 元/股） | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 1,832,421股 | | | | | ...

Group 1 - The company, Haohai Biological Technology (688366.SH), has completed its current share repurchase program as of August 14, 2025 [1] - A total of 1.8324 million A-shares were repurchased, accounting for 0.79% of the company's total share capital [1] - The highest repurchase price was 63.58 CNY per share, while the lowest was 49.25 CNY per share, with an average repurchase price of 56.70 CNY per share [1] - The total amount spent on the repurchase was 104 million CNY, excluding stamp duty and transaction commissions [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Haohai Biological Technology Co., Ltd. in the medical device industry [1][2] - As of August 15, Haohai's stock closed at 55.18 yuan, with a rolling PE ratio of 31.06 times and a total market capitalization of 12.834 billion yuan [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Haohai at the 60th position in the industry ranking [1][2] Group 2 - As of February 29, 2020, Haohai had 7,605 shareholders, an increase of 918 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business includes the research, production, and sales of medical devices and pharmaceuticals, with key products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1] - In the latest quarterly report for Q1 2025, Haohai reported revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41%, with a gross profit margin of 69.52% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Haohai Biological Technology Co., Ltd. in the medical device industry, indicating a decline in revenue and profit in the latest quarterly report [1][2] - As of August 14, Haohai's closing stock price was 54.63 yuan, with a PE ratio of 30.75 times, and a total market capitalization of 12.706 billion yuan [1] - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Haohai at the 61st rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows Haohai achieved an operating revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.3121 million yuan, down 7.41% year-on-year, with a gross profit margin of 69.52% [1] - As of February 29, 2020, Haohai had 7,605 shareholders, an increase of 918 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Summary of Key Points Core Viewpoint - The investment and financing landscape of the medical beauty injection materials industry in China is relatively mature, with a significant number of investment events and a focus on scientific research and technology services. Group 1: Financing Status - As of June 2025, there have been 39 investment events in the medical beauty injection materials industry, indicating a mature investment environment [2][4]. - The majority of financing events are concentrated in Shandong and Jiangsu provinces, with Shandong having 8 events and Jiangsu 7 events [4]. Group 2: External Investment Layout - Representative companies in the medical beauty injection materials industry have engaged in numerous external investment events, primarily focusing on scientific research and technology services, which account for approximately 58% of their investments [14][13]. - Other sectors of investment include manufacturing (18%) and wholesale and retail (8%) [14]. Group 3: Mergers and Acquisitions - The level of mergers and acquisitions in the medical beauty injection materials industry is relatively low, with notable participation from real estate companies. For instance, Lushang Development acquired 100% of Shandong Furuida Pharmaceutical Group in 2018 to enter the medical beauty sector [16].